This is part two of a trilogy on the Evolution of the Life Sciences in the UK. Read about the intro and background here. Part 1 can be found here.
Global pharmaceutical companies are revolutionising drug discovery by moving from isolated campuses to collaborative hubs. This global trend highlights the importance of cooperation and interdisciplinary connections, alongside the challenges of sourcing suitable real estate for life science innovation.
Urban Challenges and Opportunities
In urban centers like London, creating commercial lab spaces involves unique challenges, such as limited experience in lab development and scant market data on potential rents or property values. This complicates the entry into this essential market segment. As local developers attempt to fill this gap, they often seek fallback options, which are not viable for lab spaces due to their specific requirements. Despite these hurdles, the demand for lab spaces is growing, driven by experienced overseas developers accustomed to such markets.
Centralization vs. Innovation
Historically, companies like GSK and AstraZeneca established large, campus-style research centers in remote areas, a trend that originated in the U.S. and spread globally. These centers aimed to consolidate all stages of drug development from discovery to sales. However, this centralization slowed innovation, prompting a shift towards more decentralized and networked approaches. Modern pharmaceuticals are increasingly co-locating in vibrant urban areas close to universities and research institutes, fostering faster and more collaborative innovation.
(article continues below image)
Real Estate Challenges
The life science real estate market faces a shortage of properties equipped with necessary infrastructure like state-of-the-art labs and specialized equipment. This scarcity drives up leasing costs, particularly challenging for smaller firms in prime life science hubs. Furthermore, high development costs and stringent regulatory requirements increase the financial stakes for entering this market. Developers often wait to secure tenants before fully outfitting spaces with lab facilities, although overseas developers tend to prepare spaces in advance, understanding the market's needs better.
The Critical Role of Location
Location remains a dominant factor in the life science industry, unaffected by the rising trends of remote and hybrid work. Physical proximity is crucial for collaboration and access to skilled workforces and academic institutions. High real estate costs in key clusters like Oxford and Cambridge pose significant challenges, underscoring the need for strategic location decisions to reinforce and enhance life science ecosystems.
(article continues below image)
Future Outlook
While immediate changes are unlikely due to the industry's entrenched challenges, strategic efforts can mitigate these obstacles. Enhancing the integration of life science companies near academic hubs and established players can create compound benefits, promoting innovation and efficiency in drug development. The sector's growth, however, remains constrained by the high capital requirements of establishing research facilities and the complex nature of the work conducted, which demands specific types of locations and infrastructure.
The evolution of space in the pharmaceutical industry illustrates a broader move towards integration and collaboration, essential for fostering innovation in a complex and rapidly advancing field.
Key Takeaways
Things won’t change in the immediate term given some of the reasons stated, however with concerted effort earlier, some of these hurdles that hold back the growth of the industry, can be overcome. These include but not limited to:
Leading academic sites are geographically dispersed.
The national focus concentrates effort into centres of excellence.
There is compound benefit by placing innovative buildings and companies near established players.
The capital-intensive nature of research facilities and the work conducted.
Patients gather in centres of expertise built by leading specialists and key opinion leaders.
Complex medical procedures and lab experiments can only be performed in certain spaces.
This work can create an infrastructure burden and can produce hazardous outputs.
About the Authors
Dr Neha Tanna is a licensed medical doctor with many years of experience in the Biopharma industry. She works as part of senior leadership teams in the biotech industry and as a venture capital investor.
Michael Cunniffe is the Managing Director, UK of Danforth Advisors. Danforth provide development and corporate support functions on a fractional basis to high growth life science companies across all development stages, from seed to public, including IPO and fundraising transactions.
Ryan Matenchuk is a real estate finance professional with a depth of experience working in the property industry for over 20 years. He worked closely with the design and development teams, investors, vendors and debt providers to bring significant projects to life.
Comments